ANIX / Anixa Biosciences, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 ANIXA BIOS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.

Calculation of Filing Fee Table. (Filed herewith.)

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anixa Biosciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E

Code of Conduct (Filed herewith.)

Exhibit 14 Anixa Biosciences, Inc. Code Of Business Conduct And Ethics As Initially Approved by the Board of Directors January 17, 2018 This Code of Business Conduct and Ethics covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide the Company’s and its subsidiaries’ employees (collectively, “Covered Persons

As filed with the Securities and Exchange Commission on January 10, 2025

As filed with the Securities and Exchange Commission on January 10, 2025 Registration No.

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Exhibit 99.1 Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting ● Data continues positive trend as additional patients are enrolled in 3 cohorts ● Vaccine was safe and well tolerated by participants in all 3 cohorts ● Protocol defined immune responses were exhibit

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C

EX-99.2

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC

Joint Development and Option Agreement, dated May 3, 2024, between the Company and The Cleveland Clinic Foundation. (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” Joint Development and Option Agreement Preamble This Joint Development and Option Agreement (“JDA’’), effective and binding as of the last date of execution herein (“EFFECTIVE DATE”), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as “CCF”), an Ohio non-profit co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 ANIXA BIOSCIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Commis

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines – Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines –

Exhibit 99.1 Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines – Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – SAN JOSE, Calif., May 8, 2024 /PRNewswire/ - Anixa Biosciences, Inc. (“Anixa” or the

ANIX / Anixa Biosciences, Inc. / Catelani Michael Activist Investment

SC 13D 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Michael Catelani c/o Anixa Biosciences, Inc. 3150 Almaden Expressway, Suite 250 San Jose, CA 95

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 ANIXA BIOS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E

As filed with the Securities and Exchange Commission on January 16, 2024

As filed with the Securities and Exchange Commission on January 16, 2024 Registration No.

Amendment to Exclusive License Agreement between the Company and The Cleveland Clinic Foundation. (Filed herewith.)

EX-10.10 2 ex10-10.htm Exhibit 10.10

Clawback Policy (Filed herewith.)

Exhibit 99.1 ANIXA BIOSCIENCES, INC. EXECUTIVE COMPENSATION CLAWBACK POLICY Adopted as of November 17, 2023 The Board of Directors (the “Board”) of Anixa Biosciences, Inc. (the “Company”) has adopted the following executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included in

Insider Trading Policy (Filed herewith.)

Exhibit 19 Anixa Biosciences, Inc. POLICY ON INSIDER TRADING Anixa Biosciences, Inc., a Delaware corporation (the “Company”), is committed to the highest standards of ethical business conduct. This Insider Trading Policy provides the standards of the Company on trading and causing the trading of the Company’s securities or securities of other publicly-traded companies while in possession of confid

ANIX / Anixa Biosciences, Inc. / KUMAR AMIT Activist Investment

SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CU

Calculation of Filing Fee Table. (Filed herewith.)

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anixa Biosciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ANIXA BI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, inc

Exhibit 99.1 Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – –

EX-99.2

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 ANIXA BIOS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine Immune responses were observed at all dose levels

Exhibit 99.1 Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine Immune responses were observed at all dose levels SAN JOSE, Calif., April 17, 2023 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and pr

EX-99.2

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ANIXA BIOSC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Comm

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.

As filed with the Securities and Exchange Commission on January 4, 2023

As filed with the Securities and Exchange Commission on January 4, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E

Calculation of Filing Fee Table. (Filed herewith.)

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anixa Biosciences, Inc.

EX-99.2

Exhibit 99.2

Press Release

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ANIXA BI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C

EX-99.1

Exhibit 99.1

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation)

ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 September 15, 2022

CORRESP 1 filename1.htm ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 September 15, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Tyler Howes Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed September 9, 2022, as amended File No. 333-267

September 12, 2022

September 12, 2022 By EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 (File No. 333-267369) Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File No. 333-267369) filed by Anixa Biosciences, Inc. on September 9, 2022 (the ?Registration Statement?). Pursuant to Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Anixa Biosciences, Inc. (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on September 9, 2022 Registration No.

Calculation of Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anixa Biosciences, Inc.

Amendment No. 1 to Exclusive License Agreement between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended July 31, 2022.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.1 Redactions with respect to certain portions hereof denoted with ?***? AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT BETWEEN THE CLEVELAND CLINIC FOUNDATION AND ANIXA BIOSCIENCES, INC. This Amendment No. 1 to Exclusive License Agreement (this ?Amendment?), is made and entered into effective as of June 1, 2022 (the ?Amendment Date?), by and between The Cleveland Clinic Foundation (?CCF

Form of Indenture*

Exhibit 4.5 ANIXA BIOSCIENCES, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Seri

Form of Controlled Equity OfferingSM Sales Agreement (Incorporated by reference to Exhibit 10.1 to our Form S-3 dated September 9, 2022)

Exhibit 10.1 ANIXA BIOSCIENCES, INC. Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement [?], 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Anixa Biosciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance a

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,

Corporate Presentation

Exhibit 99.1

Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

Schedule 14A

DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ C

As filed with the Securities and Exchange Commission on January 4, 2022

As filed with the Securities and Exchange Commission on January 4, 2022 Registration No.

Amended and Restated Master Collaboration Agreement, dated November 1, 2021, between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Incorporated by reference to Exhibit 10.8 to our Form 10-K for the fiscal year ended October 31, 2021.)

Exhibit 10.8

Form of Warrant issued to Acorn Management Partners LLC. (Filed herewith.)

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES issuable upon exercise hereof HAS BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES OR ?BLUE SKY LAWS,? AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Co

ANIX / Anixa Biosciences Inc / KUMAR AMIT Activist Investment

SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Comm

Assignment Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended April 30, 2021.)

Exhibit 10.1 Assignment Agreement This Assignment Agreement (?ASSIGNMENT?) is entered into as of April 30, 2021, (?Effective Date?) by and between OntoChem GmbH, a German limited liability company registered at the courts of Stendal whose address is Bl?cherstrasse 24, 06120 Halle (Saale), Germany (?ASSIGNOR?), MolGenie GmbH, a German limited liability company registered at the Courts of Stuttgart

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 Commission file number 001-37492 A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc

ANIX / Anixa Biosciences Inc / KUMAR AMIT Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Amit Kumar c/o

Amendment 2 to the Collaboration Agreement between the Company and MolGenie GmbH. (Incorporated by reference to Exhibit 10.2 to our Form 10-Q for the fiscal quarter ended April 30, 2021.) (Certain information has been redacted in the marked portions of the exhibit.)

Redactions with respect to certain portions hereof denoted with ?***? Exhibit 10.2 AMENDMENT NO. 2 TO COLLABORATION AGREEMENT This AMENDMENT NO. 2 TO COLLABORATION AGREEMENT (the ?Amendment?) is made as of May 1, 2021 (the ?Amendment Effective Date?), by and between Anixa Biosciences, Inc., a Delaware corporation (?Anixa?), and MolGenie GmbH, a German limited liability company (?MolGenie?). Anixa

Corporate Presentation

Exhibit 99.1

Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Commi

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

Amendment to the Amended and Restated Bylaws of the Company. (Incorporated by reference to our Form 8-K, dated April 2, 2021.)

Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF Anixa Biosciences, Inc. (a Delaware corporation) March 29, 2021 This Amendment (the ?Amendment?) to the Amended and Restated Bylaws (the ?Bylaws?) of Anixa Biosciences, Inc., a Delaware corporation (the ?Corporation?), hereby amends the Bylaws currently in effect as follows: 1. A new Section 11.3 is hereby added to Article 11 as follows:

-

PRE 14A 1 pre14-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement

4,285,715 Shares of Common Stock Underwriter Warrants to Purchase 300,000 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-232067 PROSPECTUS SUPPLEMENT (To prospectus dated June 21, 2019) 4,285,715 Shares of Common Stock Underwriter Warrants to Purchase 300,000 Shares of Common Stock We are offering 4,285,715 shares of common stock. In addition, in connection with the offering, we are issuing common stock purchase warrants to the underwriter. These warran

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com

Amended and Restated Underwriting Agreement, dated March 22, 2021, between Anixa Biosciences, Inc. and H.C. Wainwright & Co., LLC.

Exhibit 1.1 4,285,715 SHARES of Common Stock ANIXA BIOSCIENCES, INC. AMENDED AND RESTATED UNDERWRITING AGREEMENT March 22, 2021 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned, Anixa Biosciences, Inc., a company incorporated under the laws of Delaware (col

Form of Underwriter Warrants. (Incorporated by reference to Exhibit 4.1 to our Form 8-K, dated March 24, 2021.)

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ANIXA BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: March 25, 2021 Issue Date: March 25, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after

Free Writing Prospectus

Filed pursuant to Rule 433 of the Securities Act of 1933, as amended Registration No.

Free Writing Prospectus

Filed pursuant to Rule 433 of the Securities Act of 1933, as amended Registration No.

Subject to Completion, Dated March 22, 2021

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-232067 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale is

Joint Development and Option Agreement, dated January 26, 2021, between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.2 to our Form 10-Q for the fiscal quarter ended January 31, 2021.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.2 Redactions with respect to certain portions hereof denoted with ?***? Joint Development and Option Agreement Preamble This Joint Development and Option Agreement (?JDA?), effective and binding as of the last date of execution herein (?EFFECTIVE DATE?), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as ?CCF?), an Ohio non-profit cor

Amendment to License Agreement between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended January 31, 2021.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.1 Redactions with respect to certain portions hereof denoted with ?***? AMENDMENT OF LICENSE AGREEMENT This Amendment of License Agreement (this ?Amendment?) is made as of January 22, 2021 (the ?Amendment Effective Date?), by and between The Wistar Institute of Anatomy and Biology, a nonprofit corporation organized and existing under the laws of the Commonwealth of Pennsylvania located

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of incorporation or o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1) A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Lewis H. Titte

Entry into a Material Definitive Agreement -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C

Form of Warrant issued to Acorn Management Partners LLC. (Filed herewith.).

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES issuable upon exercise hereof HAS BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES OR “BLUE SKY LAWS,” AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SU

Exclusive License Agreement, dated October 20, 2020, between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.14 to our Form 10-K, for the fiscal year ended October 31, 2020.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.14 Redactions with respect to certain portions hereof denoted with “***” EXCLUSIVE LICENSE AGREEMENT between THE CLEVELAND CLINIC FOUNDATION and ANIXA BIOSCIENCES, INC. dated as of October 20, 2020 Redactions with respect to certain portions hereof denoted with “***” EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this “Agreement”) is made and entered into effective as of

Amendment to Collaboration Agreement between the Company and OntoChem GmbH. (Incorporated by reference to Exhibit 10.13 to our Form 10-K, for the fiscal year ended October 31, 2020.)

Exhibit 10.13 AMENDMENT TO COLLABORATION AGREEMENT This AMENDMENT TO COLLABORATION AGREEMENT (the “Amendment”) is made as of October 19, 2020 (the “Amendment Effective Date”), by and between Anixa Biosciences, Inc., a Delaware corporation (“Anixa”), and OntoChem GmbH, a German limited liability company (“OntoChem”). Anixa and OntoChem are referred to herein individually as a “Party” and collective

-

As filed with the Securities and Exchange Commission on January 7, 2021 Registration No.

Subsidiaries of Anixa Biosciences, Inc. (Incorporated by reference to Exhibit 21 to our Form 10-K, for the fiscal year ended October 31, 2020.)

Exhibit 21 SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands CopyTele Marketing Inc. British Virgin Islands ITUS Patent Acquisition Corporation State of Delaware J-Channel Industries Corporation

Amendment 2 to the Collaboration Agreement between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Filed herewith.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.10 Redactions with respect to certain portions hereof denoted with “***” AMENDMENT 2 TO THE COLLABORATION AGREEMENT BETWEEN CERTAINTY THERAPEUTICS, INC. AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. Moffitt Agreement Identifier: Anixa-CERTainty Contract (Conejo-Garcia) 17-0173 Project Title: Development of CAR-T/CER-T Therapies for Ovarian and Prostate Cancer Moffitt Pri

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC

Code of Conduct (Incorporated by reference to Exhibit 14 to our Form 10-K, for the fiscal year ended October 31, 2020.)

Exhibit 14 Anixa Biosciences, Inc. Code Of Business Conduct And Ethics As Approved by the Board of Directors January 17, 2018 This Code of Business Conduct and Ethics covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide the Company’s principal executive officer, principal financial officer, principal accou

Entry into a Material Definitive Agreement -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (

Corporate Presentation

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation)

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of incorporation or orga

1

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Certificate of Amendment to the Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to our Form 8-K, dated August 13, 2020.)

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ANIXA BIOSCIENCES, INC. The undersigned, for the purposes of amending the Certificate of Incorporation of Anixa Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The Board of

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Co

- DEFA 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commi

- DEF 14A

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.

Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio

Exhibit 99.1 Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio SAN JOSE, Calif., July 2, 2020 /PRNewswire/- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and

- PRELIMINARY PROXY STATEMENT

PRE 14A 1 pre14a.htm PRELIMINARY PROXY STATEMENT SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a

Collaboration Agreement, dated April 14, 2020, between the Company and OntoChem GmbH. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended April 30, 2020.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is made as of April 14th, 2020 (the “Effective Date”) by and between Anixa Biosciences, Inc., a Delaware corporation, located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A. (“Anixa”), and OntoChem GmbH, a German limited liabili

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incor

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com

ANIX / Anixa Biosciences Inc 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc

ANIX / Anixa Biosciences Inc 10-K/A - Annual Report - FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment No. 1) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ANIXA

Subsidiaries of Anixa Biosciences, Inc. (Incorporated by reference to Exhibit 21 to our Form 10-K, dated January 9, 2020)

Exhibit 21 SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands CopyTele Marketing Inc. British Virgin Islands ITUS Patent Acquisition Corporation State of Delaware J-Channel Industries Corporation

Prospectus Supplement No. 1 to Reoffer Prospectus Anixa Biosciences, Inc. Up to 7,030,112 Shares of Common Stock under the 2018 Share Incentive Plan, Employee Stock Purchase Plan, 2010 Share Incentive Plan, as amended, certain Non-Plan Time Based Sto

Filed Pursuant to Rule 424(b)(3) Registration No. 333- 227653 Prospectus Supplement No. 1 to Reoffer Prospectus of Anixa Biosciences, Inc. Up to 7,030,112 Shares of Common Stock under the 2018 Share Incentive Plan, Employee Stock Purchase Plan, 2010 Share Incentive Plan, as amended, certain Non-Plan Time Based Stock Option Agreements and certain Non-Plan Performance Based Stock Option Agreements T

ANIX / Anixa Biosciences Inc 10-K - Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ANIXA BIOSCIENCES, INC.

Amended and Restated By-laws. (Incorporated by reference to Exhibit 3.8 to our Form 10-K for the fiscal year ended October 31, 2019.)

Exhibit 3.8 AMENDED AND RESTATED BYLAWS OF ANIXA BIOSCIENCES, INC. (a Delaware Corporation) (Adopted Effective as of January 6, 2020) These Amended and Restated Bylaws of Anixa Biosciences, Inc., a Delaware corporation (the “Corporation”), are adopted pursuant to Article 12 of the Corporation’s existing Bylaws (the “Original Bylaws”) and are intended to amend, restate and replace, in their entiret

1

EX-99.1 2 exhibit991.htm EXHIBIT 99.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C

ANIX / Anixa Biosciences Inc DEF 14A - - DEF 14A

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.

Exclusive License Agreement, dated July 8, 2019, between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended July 31, 2019.) (Certain information has been redacted in the marked portions of the exhibit.)

Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” EXCLUSIVE LICENSE AGREEMENT between THE CLEVELAND CLINIC FOUNDATION and ANIXA BIOSCIENCES, INC. dated as of July 8, 2019 Redactions with respect to certain portions hereof denoted with “***” EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this “Agreement”) is made and entered into effective as of July

ANIX / Anixa Biosciences Inc 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorp

Amendment 1 to the Collaboration Agreement between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Incorporated by reference to Exhibit 10.2 to our Form 10-Q for the fiscal quarter ended July 31, 2019.)

Exhibit 10.2 AMENDMENT 1 TO THE COLLABORATION AGREEMENT BETWEEN CERTAINTY THERAPEUTICS, INC. AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. Moffitt Agreement Identifier: Anixa-CERTainty Contract (Conejo-Garcia) 17-0173 Project Title: Development of CAR-T/CER-T Therapies for Ovarian and Prostate Cancer Moffitt Principle Investigator: Dr. Jose Conejo-Garcia The Agreement described abo

Financial Statements and Exhibits, Other Events

8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdic

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE THOMAS S. HOWLAND, JR., derivatively on behalf of ANIXA BIOSCIENCES, INC. (f/k/a ITUS CORPORATION), Plaintiff, v. AMIT KUMAR, LEWIS H. TITTERTON, JR., ARNOLD M. BASKIES, JOHN MONAHAN, MICHAEL J. CATELANI, C.A. No.: 2018-0804-KSJM JOHN A. ROOP, ANTHONY CAMPISI, and DALE FOX, Defendants, and ANIXA BIOSCIENCES, INC. (f/k/a ITUS CORPORATION), Nominal D

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Co

1

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Entry into a Material Definitive Agreement

8-K 1 form8k.htm FORM8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction

ANIX / Anixa Biosciences Inc CORRESP - -

ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 June 19, 2019 VIA EDGAR U.S. Securities and Exchange Commission Office of Financial Services 100 F Street, N.E. Mail Stop 4628 Washington, DC 20549 Attn: Ronald Alper Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed June 11, 2019 File No. 333-232067 Dear Mr. Alper: Pursuant to Rule 461 under the Secur

ANIX / Anixa Biosciences Inc 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incor

At Market Issuance Sales Agreement, dated June 21, 2019, between the Company and B. Riley FBR, Inc. (Incorporated by reference to Exhibit 10.1 to our Registration Statement of Form S-3 filed June 11, 2019.)

EX-10.1 4 exhibit101.htm EXHIBIT 10.1 Exhibit 10.1 ANIXA BIOSCIENCES, INC. Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement June [•], 2019 B. Riley FBR, Inc. 299 Park Avenue, 21st Floor New York, NY, 10171 Ladies and Gentlemen: Anixa Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley FBR, Inc. (the “Agent”)

ANIXA BIOSCIENCES, INC., as [ ], as INDENTURE TRUSTEE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of

Exhibit 4.5 ANIXA BIOSCIENCES, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Seri

ANIX / Anixa Biosciences Inc S-3 - - FORM S-3

As filed with the Securities and Exchange Commission on June 11, 2019 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commi

1

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

ANIX / Anixa Biosciences Inc FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc

Financial Statements and Exhibits, Other Events

8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdi

Anixa Biosciences Conference Call Recording Available on Company Website

Exhibit 99.1 Anixa Biosciences Conference Call Recording Available on Company Website SAN JOSE, Calif., January 25, 2019 /PRNewswire/ - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, today announced that it has made a recording of its January 24, 2019 conference call available on its website. The recording can be found on

SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Isl

Exhibit 21 SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands CopyTele Marketing Inc. British Virgin Islands ITUS Patent Acquisition Corporation State of Delaware J-Channel Industries Corporation

ANIX / Anixa Biosciences Inc FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ANIXA BIOSCIENCES, INC.

ANIX / Anixa Biosciences Inc / KUMAR AMIT - SCHEDULE 13D/A Activist Investment

SC 13D/A 1 schedule13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109

Table of Contents

As filed with the Securities and Exchange Commission on October 1, 2018 Registration No.

Form of Stock Option Agreement (Incorporated by reference to Exhibit 4.14 of our Registration Statement on Form S-8 filed on October 1, 2018.)

Exhibit 4.14 408.708.9808 NASDAQ: ITUS [Grant Date] [Employee] c/o ITUS Corporation 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 RE: Grant of Stock Option to Employee Dear [Employee]: On January 25, 2018, the Board of Directors of ITUS Corporation (the "Company") adopted the ITUS Corporation 2018 Share Incentive Plan (as the same was approved by the stockholders of the Company on March 29

Form of Restricted Stock Award (Incorporated by reference to Exhibit 4.15 of our Registration Statement on Form S-8 filed on October 1, 2018.)

Exhibit 4.15 ITUS CORPORATION 2018 SHARE INCENTIVE PLAN Award Agreement This Award Agreement evidences an Award of shares of Restricted Stock pursuant to the provisions of the ITUS Corporation 2018 Share Incentive Plan (the “Plan”) to the individual whose name appears below (the “Participant”), on the following express terms and conditions (capitalized terms not otherwise defined herein shall have

2018 Share Incentive Plan. (Incorporated by reference to Exhibit 4.13 to our Form S-8 dated October 1, 2018.)

Exhibit 4.13 ITUS CORPORATION 2018 SHARE INCENTIVE PLAN 1. Purpose. The ITUS Corporation 2018 Share Incentive Plan (the "Plan") is intended to provide incentives which will attract, retain and motivate highly competent persons as officers, employees and non-employee directors ("Director Participants"), of, and consultants to, ITUS Corporation (the "Company") and its subsidiaries and affiliates, by

Employee Stock Purchase Plan (Incorporated by reference to Exhibit 4.16 of our Registration Statement on Form S-8 filed on October 1, 2018.)

Exhibit 4.16 ITUS CORPORATION EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the ITUS Corporation Employee Stock Purchase Plan (the “Plan”), as adopted by the Board of Directors of the Company (the “Board”) and subsequently approved by the shareholders of the Company, is to encourage and facilitate the ownership of shares of common stock of the Company by eligible employees of the Company

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2018 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other juris

Certificate of Amendment to the Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to our Form 8-K, dated October 1, 2018.)

EX-3.1 2 exhibit31.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ITUS CORPORATION The undersigned, for the purposes of amending the Certificate of Incorporation of ITUS Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: FIRST: The B

AMENDED AND RESTATED BYLAWS OF ANIXA BIOSCIENCES, INC. (a Delaware Corporation) (Adopted Effective as of October 1, 2018)

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ANIXA BIOSCIENCES, INC. (a Delaware Corporation) (Adopted Effective as of October 1, 2018) These Amended and Restated Bylaws of Anixa Biosciences, Inc., a Delaware corporation (formerly ITUS Corporation, the “Corporation”), are adopted pursuant to Article XIV of the Corporation’s existing Bylaws (the “Original Bylaws”) and are intended to amend, restate a

EX-99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commis

ITUS / ITUS Corp. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2018 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporation

ITUS / ITUS Corp. DEF 14A

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 ITUS Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission

ITUS / ITUS Corp. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2018 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporatio

Certificate of Amendment to the Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to our Form 10-Q for the fiscal quarter ended April 30, 2018.)

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ITUS CORPORATION The undersigned, for the purposes of amending the Certificate of Incorporation of ITUS Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: FIRST: The Board of Directors of the Corporatio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission Fi

ITUS / ITUS Corp. FORM 144

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. OMB APPROVAL OMB Number: 3235-0101 Expires: June 30,

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement March 27, 2018 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171

Exhibit 10.1 ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement March 27, 2018 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 Ladies and Gentlemen: ITUS Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley FBR, Inc. (the “Agent”) as follows: 1. Issuance and Sale of Shares. The Compa

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission

ITUS CORPORATION Up to 2,200,000 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220963 Prospectus Supplement (To prospectus dated October 16, 2017) ITUS CORPORATION Up to 2,200,000 Shares of Common Stock We have entered into an At Market Issuance Sales Agreement with B. Riley FBR, Inc. (“B. Riley FBR”) relating to the sale of our common stock offered by this prospectus supplement and the accompanying prospectus.

ITUS / ITUS Corp. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2018 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporat

ITUS Corporation Forms Alliance with Serametrix Corporation

Exhibit 99.1 ITUS Corporation Forms Alliance with Serametrix Corporation SAN JOSE, CA – March 5, 2018: ITUS Corporation (NASDAQ: ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS’s proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix’s substantial expertise in immune monitoring assays. Serametrix flow c

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission

ITUS / ITUS Corp. / Titterton Lewis H jr - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. ) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Lewis H. Titterton Jr. 1900 Purdue A

Exhibit 23.1

Exhibit 23.1 Table of Contents Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-8 of ITUS Corporation (the ?Company?) of our report dated January 9, 2018, relating to our audits of the Company?s consolidated financial statements as of October 31, 2017 and 2016, and for each of the years ended

Table of Contents

Form S-8 As filed with the Securities and Exchange Commission on February 14, 2018 Registration No.

ITUS / ITUS Corp. DEF 14A

DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 ITUS Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.

ITUS / ITUS Corp. / Eames Bruce Paul - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ITUS Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45069V203 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate the rule pur

ITUS / ITUS Corp. / Eames Bruce Paul - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 – Exit Filing)* ITUS Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45069V203 (CUSIP Number) January 9, 2018 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate

ITUS / ITUS Corp. PRELIMINARY PROXY STATEMENT

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 ITUS Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (

License Agreement, dated November 13, 2017, between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. (Incorporated by reference to Exhibit 10.14 to our Form 10-K, dated January 9, 2018.) (Portions of this exhibit have been redacted pursuant to a request for confidential treatment. The redacted portions have been separately filed with the Securities and Exchange Commission.)

Exhibit 10.14 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) Is made as of the 13th day of November, 2017 (the “Effective Date”), by and between THE WIS

Collaboration Agreement, dated November 17, 2017, between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Incorporated by reference to Exhibit 10.15 to our Form 10-K, dated January 9, 2018.) (Portions of this exhibit have been redacted pursuant to a request for confidential treatment. The redacted portions have been separately filed with the Securities and Exchange Commission.)

Exhibit 10.15 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” COLLABORATION AGREEMENT THIS AGREEMENT is entered into on November 17, 2017 (hereinafter “Effective Date) by and between H. Lee Moffitt Cancer Center

SUBSIDIARIES OF ITUS CORPORATION Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostic Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands Cop

Exhibit 21 SUBSIDIARIES OF ITUS CORPORATION Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostic Corporation State of Delaware Certainty Therapeutics, Inc.

ITUS / ITUS Corp. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ITUS CORPORATION (Exact

Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” SECOND AMENDME

Exhibit 99.3 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” SECOND AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT This SECOND AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT (the “Second Amendment”) is made

Termination of a Material Definitive Agreement

form 8k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (

Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)

Entry into a Material Definitive Agreement

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement

Exhibit 10.1 ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement November 17, 2017 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 Ladies and Gentlemen: ITUS Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with B. Riley FBR, Inc. (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The Co

ITUS CORPORATION Up to 3,000,000 Shares of Common Stock

Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220963 Prospectus Supplement (To prospectus dated October 16, 2017) ITUS CORPORATION Up to 3,000,000 Shares of Common Stock We have entered into an At Market Issuance Sales Agreement with B. Riley FBR, Inc. (?B. Riley FBR?) relating to the sale of our common stock offered by this prospectus supplement and the acc

ITUS / ITUS Corp. ESP

S-3 Acceleration Request ITUS CORPORATION 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 October 24, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

ITUS FORM S-3

form S-3 As filed with the Securities and Exchange Commission on October 13, 2017 Registration No.

Financial Statements and Exhibits, Other Events

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C

ITUS Receives Notice of NASDAQ Continued Listing Compliance

Exhibit 99.1 Exhibit 99.1 ITUS Receives Notice of NASDAQ Continued Listing Compliance SAN JOSE, CA ? October 3, 2017: ITUS Corporation (NASDAQ: ITUS) today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has regained compliance with the minimum bid price requirement of The Nasdaq Stock Market as required for continu

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement

Exhibit 10.1 Exhibit 10.1 ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement September 28, 2017 FBR Capital Markets & Co. 1300 North 17th Street Suite 1400 Arlington, Virginia 22209 Ladies and Gentlemen: ITUS Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with FBR Capital Markets & Co. (?FBR?) as follows: 1.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2017 (September 28, 2017) ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdic

Units

Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-206782 Prospectus Supplement (To prospectus dated September 14, 2015) ITUS CORPORATION Up to $3,669,043 Common Stock We have entered into an At Market Issuance Sales Agreement with FBR Capital Markets & Co. (?FBR?) relating to the sale of our common stock offered by this prospectus supplement and the accompanying

Submission of Matters to a Vote of Security Holders

Form-8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)

ITUS / ITUS Corp. / Eames Bruce Paul - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* ITUS Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45069V203 (CUSIP Number) March 27, 20

ITUS / ITUS Corp. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2017 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporation

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C

Other Events

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C

ITUS DEF 14A

DEF 14A 1 def14a.htm DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant  Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rul

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Comm

ITUS / ITUS Corp. / BERMAN ROBERT ANDREW - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Robert A. Berman c/o ITUS Corporati

ITUS / ITUS Corp. / KUMAR AMIT - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Amit Kumar c/o ITUS Corporation 121

Regulation FD Disclosure, Financial Statements and Exhibits

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Comm

EX-99.1

EX-99.1 2 exhibit991.htm EXHIBIT 99.1

ITUS FORM 10-Q (Quarterly Report)

Form 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2017 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of in

2. Fees; Expenses; Other Arrangements.

Exhibit 10.1 Exhibit 10.1 PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 1 North Federal Highway Boca Raton, Florida 33432 May 11, 2017 Ladies and Gentlemen: This letter (this ?Agreement?) constitutes the agreement between ITUS Corporation, a Delaware corporation (the ?Company?) and Dawson James Securities, Inc. (?Dawson? or the ?Placement Agent?) pursuant to which Dawson shall serve as

Units

424B2 1 prospectus.htm FORM 424B Filed pursuant to Rule 424(b)(2) Registration Statement No. 333-206782 Prospectus Supplement (To prospectus dated September 14, 2015) ITUS CORPORATION 3,500,000 Shares of Common Stock We are offering 3,500,000 of our common stock, par value $0.01 per share, for a purchase price equal to $1.05 per share. For a description of our common stock, see the section entitle

Units

Prospectus Supplement The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

Other Events

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Co

ITUS ESP

S-3 Acceleration Request ITUS CORPORATION 12100 Wilshire Boulevard, Suite 1275 Los Angeles, CA 90025 April 6, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

ITUS FORM 8-K (Current Report/Significant Event)

Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com

ITUS Announces Closing of Rights Offering

Exhibit 99.1 Exhibit 99.1 ITUS Announces Closing of Rights Offering LOS ANGELES, CA ? April 4, 2017: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), announced that its rights offering of common shares closed today, raising gross proceeds of approximately $4.7 million before payment of dealer manager fee and other expenses, through the issuance of 1,989,207 shares of common stock. Robert Berman, ITUS?s P

ITUS FORM S-3

S-3 As filed with the Securities and Exchange Commission on March 31, 2017 Registration No.

AGREEMENT

Exhibit 99.1 Exhibit 99.1 AGREEMENT This agreement ("Agreement") is entered into this 11 day of November, 2013 (the "Effective Date"), by and between Meetrix Communications, Inc. ("Assignor"), a corporation with an address at c/o AVG Ventures 500 Ygnacio Valley road, Suite 360 Walnut Creek, CA 94596, and CTI PATENT ACQUISITION CORPORATION ("CTIPAC"), a Delaware corporation, having a principal plac

ITUS REQUEST WITHDRAWAL OF S-1 FILE NO. 333-215799

Form RW ITUS CORPORATION 12100 Wilshire Boulevard, Suite 1275 Los Angeles, CA 90025 March 24, 2017 VIA EDGAR Securities and Exchange Commission 100 F.

ITUS FORM 10-Q (Quarterly Report)

Form 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2017 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer i

1. The Rights Offering.

Exhibit 10.1 Exhibit 10.1 DEALER-MANAGER AGREEMENT March 3, 2017 Advisory Group Equity Services, Ltd. doing business as RHK Capital As Dealer-Manager 444 Washington Street, Suite 407 Woburn, Massachusetts 01801 Ladies and Gentlemen: The following will confirm our agreement relating to the proposed subscription rights offering (the ?Rights Offering?) to be undertaken by ITUS Corporation, a Delaware

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of i

QUESTIONS AND ANSWERS RELATING TO THE RIGHTS OFFERING THE RIGHTS OFFERING MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES PLAN OF DISTRIBUTION Units

424B2 1 prospectus.htm FORM 424B Filed pursuant to Rule 424(b)(2) Registration Statement No. 333-206782 Prospectus Supplement (To prospectus dated September 14, 2015) ITUS CORPORATION 9,066,987 Subscription Rights to Purchase Shares of Common Stock and Up to 3,703,703 Shares of Common Stock Issuable upon Exercise of Subscription Rights We are distributing to the holders of our common stock and cer

ITUS FORM 8-K (Current Report/Significant Event)

form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)

ITUS Extends Ownership Period and Changes Record Date for Stock Rights Offering

Exhibit 99.1 Exhibit 99.1 ITUS Extends Ownership Period and Changes Record Date for Stock Rights Offering LOS ANGELES, CA ? February 10, 2017: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), a company using the power of the immune system for early cancer detection, is changing the Record Date for its current stock rights offering. The new Record Date will be Wednesday March 1, 2017. For new shareholders

Meetrix will experience immediate and substantial dilution as a result of this issuance.

As filed with the Securities and Exchange Commission on January 27, 2017 Registration No.

ITUS Announces Common Stock Rights Offering and Ownership Day

Exhibit 99.1 ITUS Announces Common Stock Rights Offering and Ownership Day LOS ANGELES, CA ? January 19, 2017: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), a company developing Cchek?, a cancer diagnostic platform based on the body?s immunological response to a malignancy, today announced that its board of directors has approved a rights offering for ITUS shareholders of up to $12,000,000. The rights

ITUS FORM 8-K (Current Report/Significant Event)

form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (

ITUS / ITUS Corp. / Titterton Lewis H jr - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (Amendment No. ) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

ITUS FORM 10-K/A (Annual Report)

form10K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment No. 1) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11

ITUS FORM 8-K (Current Report/Significant Event)

form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (

ITUS Announces CchekÔ Preliminary Cancer Patient Efficacy Study Results

Exhibit 99.1 Exhibit 99.1 ITUS Announces Cchek? Preliminary Cancer Patient Efficacy Study Results LOS ANGELES, CA ? December 7, 2016: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), today announced preliminary results from its Cchek? cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient?s immunological response to a malignancy, the Company achieved Sensitivit

ITUS FORM 10-K (Annual Report)

form10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ITUS CORPORATION

Form of Warrant issued to Adaptive Capital LLC. (Incorporated by reference to Exhibit 4.2 to our Form 10-K, dated December 7, 2016.).

Exhibit 4.2 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE OFFERED FOR SALE, SOLD,ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A)

Letter Agreement, dated October 17, 2016, between the Company and Mike Catelani. (Incorporated by reference to Exhibit 10.21 to our Form 10-K, dated December 7, 2016.)

Exhibit 10.21 ITUS CORPORATION October 17, 2016 Mr. Mike Catelani Re: Employment - CFO Position ITUS Corporation Dear Mike: We are pleased to extend you an offer for full time employment at ITUS Corporation (the "Company") as Chief Financial Officer. As we discussed, our current CFO is on part time status, and will be retiring on December 31, 2016. We would like you to join the Company as of Novem

ITUS CORPORATION 12% Secured Debenture Due November 11, 2017

Exhibit 10.20 ITUS CORPORATION 12% Secured Debenture Due November 11, 2017 $3,000,000 ITUS Corporation., a Delaware corporation (the “Company” or “Maker”), for value received, hereby promises to pay to Adaptive Capital LLC or its registered assigns (the “Payee” or “Holder”), at 500 Ygnacio Valley Road, Suite 360 Walnut Creek, CA 94596 upon due presentation and surrender of this twelve percent (12%

Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” COLLABORATIVE

Exhibit 99.1 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” COLLABORATIVE RESEARCH AGREEMENT This COLLABORATIVE RESEARCH AGREEMENT (the “Agreement”) is made as of the 14th day of July, 2015 (the “Effective Date”

LETTER AGREEMENT

Exhibit 10.19 LETTER AGREEMENT This Letter Agreement (the “Agreement”) is entered into by and between ITUS Corporation, a Delaware corporation (the “Company”), and Adaptive Capital LLC (“Adaptive”). WHEREAS, Adaptive is the holder of 3,500 shares of Series A Convertible Preferred Stock (the “Preferred Stock”) representing all of the issued and outstanding shares of preferred stock of the Company;

SUBSIDIARIES OF ITUS CORPORATION

Exhibit 21 SUBSIDIARIES OF ITUS CORPORATION Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation Sate of Delaware CopyTele International Ltd.

Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” COLLABORATIVE

Exhibit 99.3 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” COLLABORATIVE RESEARCH AGREEMENT This COLLABORATIVE RESEARCH AGREEMENT (the “Agreement”) is made as of the 4th day of August, 2016 (the “Effective Date

Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” FIRST AMENDMEN

Exhibit 99.2 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT This FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT (the “First Amendment”) is made as

ITUS / ITUS Corp. / Titterton Lewis H jr - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Lewis H. Titterton Jr. 1900 Purdy A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)

ITUS Receives Notice of NASDAQ Continued Listing Compliance

Exhibit 99.1 Exhibit 99.1 ITUS Receives Notice of NASDAQ Continued Listing Compliance LOS ANGELES, CA ? October 17, 2016: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has evidenced compliance with all requirements for continued listing on The Nasdaq Capital Market.

ITUS FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)

ITUS FORM 8-K (Current Report/Significant Event)

FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdictionof incorporation) (C